NCT07215962View on ClinicalTrials.gov

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Active, not recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

March 1, 2026

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
BIOLOGICAL

Nivolumab + ipilimumab

According to the product label

BIOLOGICAL

Nivolumab + ipilimumab + platinum-based chemotherapy

According to the product label

BIOLOGICAL

Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy

According to the product label

BIOLOGICAL

Other dual-immuno-oncology therapy with chemotherapy

According to the product label

Trial Locations (1)

32003

Florida Cancer Specialists & Research Institute, Fleming Island

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY